Evotec SE

Evotec SE and Odyssey Therapeutics have entered a strategic R&D collaboration to discover potential new treatments for autoimmune and inflammatory diseases. Under the agreement, Odyssey will leverage Evotec's integrated data-driven discovery platform, advanced screening capabilities, and AI-enabled data science technologies to discover and validate differentiated small molecule drug candidates across multiple high-value disease targets. The collaboration combines Odyssey's disease biology expertise with Evotec's proprietary compound libraries and discovery infrastructure to accelerate early-stage research. Evotec is eligible to receive milestone payments based on the successful delivery of validated hit series for each target, though detailed financials were not disclosed.

The global cell-based assay services for preclinical use only market reached approximately $4.47 billion in 2025 and is projected to grow to $12.93 billion by 2035, according to a new report from ResearchAndMarkets.com. The market recorded a compound annual growth rate of 12.3% from 2020 and is forecast to expand at 11.5% through 2030 before reaching the 2035 figure. Cytotoxicity assays were the largest segment in 2025, accounting for 30.8% of the market, while phenotypic and morphological assays are expected to be the fastest-growing category through 2030. North America led regional revenue with a 40.1% share in 2025, but Asia-Pacific is forecast to be the fastest-growing region with a 15.2% CAGR through 2030. Leading companies profiled include Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, and Evotec, with the top 10 competitors holding 19.17% of the market in 2024.

Evotec has introduced J.TRAIN, a turnkey solution that lets biopharmaceutical companies deploy its proprietary continuous manufacturing technology in their own facilities. The offering combines modular cleanrooms, industry-standard equipment, and cGMP-compliant process automation to deliver faster, more cost-effective biologics production than traditional fed-batch methods. Partners can establish on-site manufacturing capacity in as little as 18 months, with embedded automation, digital validation, and training protocols to streamline implementation and ensure regulatory readiness. Evotec says the model represents a shift toward a capital-lighter, technology-focused business, validated by its December 2025 transaction with Sandoz that included a facility and a license to the technology. The platform was unveiled at the INTERPHEX conference in New York in April 2026.